Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

Cyanovrin Conjugates and Matrix-Anchored Cyanovrin and Anti-Cyanovirin and Related Compositions and Methods of Use

  • Read more about Cyanovrin Conjugates and Matrix-Anchored Cyanovrin and Anti-Cyanovirin and Related Compositions and Methods of Use
European Patent
00913869.4
Filed on 2000-03-10

NOVEL B-LYMPHOMA CELL LINE AND ANTIGEN

  • Read more about NOVEL B-LYMPHOMA CELL LINE AND ANTIGEN
European Patent
93920252.9
Filed on 1993-08-20

CALANOLIDE ANTIVIRAL COMPOUNDS; COMPOSITIONS AND USES THEREOF

  • Read more about CALANOLIDE ANTIVIRAL COMPOUNDS; COMPOSITIONS AND USES THEREOF
Canada
2133080
Filed on 1993-03-24

CALANOLIDES, NOVEL ANTIVIRAL COMPOUNDS; COMPOSITIONS AND USES THEREOF

  • Read more about CALANOLIDES, NOVEL ANTIVIRAL COMPOUNDS; COMPOSITIONS AND USES THEREOF
Australia
39355/93
Filed on 1993-03-24

MIXED LIGAND METAL COMPLEXES OF NITRIC OXIDE NUCLEOPHILE ADDUCTS USEFUL AS CARDIOVASCULAR AGENTS

  • Read more about MIXED LIGAND METAL COMPLEXES OF NITRIC OXIDE NUCLEOPHILE ADDUCTS USEFUL AS CARDIOVASCULAR AGENTS
Spain
93908556.9
Filed on 1993-03-24

MIXED LIGAND METAL COMPLEXES OF NITRIC OXIDE NUCLEOPHILE ADDUCTS USEFUL AS CARDIOVASCULAR AGENTS

  • Read more about MIXED LIGAND METAL COMPLEXES OF NITRIC OXIDE NUCLEOPHILE ADDUCTS USEFUL AS CARDIOVASCULAR AGENTS
The Netherlands
93908556.9
Filed on 1993-03-24

METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS FROM mRNA

  • Read more about METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS FROM mRNA
Canada
2132208
Filed on 1993-03-29

METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS FROM mRNA

  • Read more about METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS FROM mRNA
Australia
39694/93
Filed on 1993-03-29

Peptides Stimulating Cytotoxic Lymphocytes Response to HIV-1 GP 160

  • Read more about Peptides Stimulating Cytotoxic Lymphocytes Response to HIV-1 GP 160
European Patent
93907180.9
Filed on 1993-03-06

POTENT PEPTIDE FOR STIMULATION OF CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR THE HIV-1 ENVELOPE

  • Read more about POTENT PEPTIDE FOR STIMULATION OF CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR THE HIV-1 ENVELOPE
Canada
2131153
Filed on 1993-03-08

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 1247
  • Page 1248
  • Page 1249
  • Page 1250
  • Page 1251
  • Page 1252
  • Page 1253
  • Page 1254
  • Page 1255
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health